Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Oncology Letters|February 2, 2018
A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemiaJiabao Liang, Pengcheng Shi, Xutao Guo, et al.Pharmacogenomics|December 21, 2012
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expressionPengcheng Shi, Jie Zha, Xutao Guo, et al.Pharmacogenomics|December 15, 2016
Allogeneic hematopoietic stem cell transplantation improves the prognosis of p16-deleted adult patients with acute lymphoblastic leukemiaYan Wang, Guoshu Chen, Rui Cao, et al.Leukemia & Lymphoma|July 12, 2022
CD43 is an adverse prognostic factor in newly diagnosed multiple myelomaXueqin Ning, Xiaolei Wei, Bingyuan Chen, et al.European Journal of Pharmacology|November 14, 2018
Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathwayYan Wang, Manman Deng, Qinwei Chen, et al.Journal of Materials Chemistry. B|April 21, 2023
Green synthesis of mesoporous and biodegradable iron silicide nanoparticles for photothermal cancer therapyXutao Guo, Shuxian Wang, Shubin Wang, et al.Transplantation|July 12, 2013
Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantationLi Xuan, Xinmiao Jiang, Jing Sun, et al.Oncotarget|April 16, 2016
Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCTLi Xuan, Zhiping Fan, Yu Zhang, et al.Journal of Hematology & Oncology|February 12, 2013
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter studyHui Liu, Xiao Zhai, Zhaoyang Song, et al.Leukemia & Lymphoma|April 24, 2026
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphomaLina Hu, Bo Lu, Xiaolei Wei, et al.Pageof 4